Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
2 reports, 1 independent
Updated Sep 22
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
The entities involved
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
-
Merck
public company in Indonesia
- FDA
Related events
- An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- Merck has set the list price for a drug that received approval from the FDA.
- A product was launched in the U.S. market following FDA involvement.
- FDA and Pfizer are seeking regulatory approval for their products.